KRAS and colorectal carcinoma: These results are significant as they indicate that the expression level of PRMT5 is correlated with the mutation status of KRAS. In light of these findings, we therefore hypothesized that PRMT5 inhibition may show greater effects in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells.